It’s Thanksgiving week and, as most of our listeners know, it’s time when Inside Workers’ Comp celebrates our annual tradition by presenting our “Why We’re Thankful for Workers’ Comp” episode. This year, we open the floor to members of our Enlyte parent brand and pose the question to key players in our industry: Rebecca Morgan, VP, Product Management, Mitchell; Anne Levins, SVP, Network Product & Analytics, Coventry; and Debbi Gillespie, RN, CCM, Heart of Case Management Award Winner, Genex. Listen and learn why they believe this year’s Thanksgiving will be extra special for workers’ comp professionals.
More stories
Resilience Redefines Results
Join our upcoming webinar to discover how resilience can be a game-changer in driving better outcomes for injured employees. From accelerating recovery to improving return-to-work success, resilience plays a critical role in both mental and physical well-being.
Practical Application of Behavioral Coaching Techniques
This case study showcases the power of behavioral coaching techniques in transforming an injured employee’s recovery. Through empathy, active listening, and strategic intervention, Enlyte’s Telephonic Case Manager helped break barriers to healing—leading to improved outcomes, renewed engagement and meaningful cost savings.
From Setback to Comeback: Effective Solutions for Delayed Recovery
Learn how to effectively ignite workers' compensation recovery by addressing some of the biggest return-to-work obstacles, including mental health comorbidities, social factors, and delayed intervention. See how data-driven strategies lead to successful claims management and faster employee recovery.
Pulsing Recovery: Bone Growth Stimulation's Impact on Comp
Discover how bone growth stimulators are accelerating recovery in workers’ comp. Nicole Usher joins the Enlyte Envision podcast to discuss how BGS devices support healing in complex fractures and spinal surgeries.
Ask The Pharmacist: FDA Approval of Non-Opioid Medication for Acute Pain
The U.S. Food and Drug Administration (FDA) recently approved Journavx (suzetrigine), a novel non-opioid medication developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. This approval, announced on January 30, 2025, marks a significant milestone in pain management, introducing the first new class of oral medication for acute pain in over two decades.
The AI Balancing Act: Navigating Innovation in Workers’ Compensation
Industry expert Michael Cwynar of Enlyte discusses how to strike the right balance between AI innovation and professional expertise in today’s rapidly evolving tech landscape.